Markets
Burning Rock Biotech Limited (BNR)
BNRNASDAQ-GMMedical Specialities
$12.83
-0.0850 (-0.66%) today
Regular session, Nov 10, 12:17 PM ET
-0.66% 1D
- Market cap
- $135.26m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- $12.37 to $13.36
- 52-week range
- $6.79 to $41.72
- Average volume
- 41.9k
- Previous close
- $12.91
Financials
| Quarter | Mar 2020 |
|---|---|
| Revenue | $9.49m |
| Gross profit | $6.31m |
| Operating income | -$8.37m |
| Net income | -$7.41m |
News
4 latest- Burning Rock Q2 Revenue Falls 9%; In-Hospital Business Posts Growth RTTNews · Sep 10, 2026
- Burning Rock Biotech Loss Shrinks In Q2 RTTNews · Sep 8, 2025
- Burning Rock Biotech Limited Reports Q1 2025 Financial Results and Advances in Oncology ResearchQuiver Quantitative · Jun 6, 2025
- Burning Rock Biotech Limited Reports Fourth Quarter and Full Year 2024 Financial Results, Highlighting Progress Towards ProfitabilityQuiver Quantitative · Mar 25, 2025
The company
Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to guard life via science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, and ii) cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.
- Sector
- Health Care
- Industry
- Medical Specialities
- Exchange
- NASDAQ-GM
- Region
- Asia
- Website
- brbiotech.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.